Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval

Benzinga · 1d ago
  • Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval 
  •  Marks the second US FDA Orphan Drug Designation for sovleplenib, following its recent designation for primary ITP